Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Category
Global or ExUS Equities - Industry Sector
Sponsor
Blackrock (iShares)
Fund Family
Index
NYSE FactSet Global Genomics and Immuno...
Index Weighting
Active/Passive
Expense
0.47%
Inverse/Leveraged
IPO
Jun 13, 2019
Asset Type
Equities (Stocks)
ETF Type
Bond Type
Average Maturity
Commodity Type
Quant Type
ESG Type
Dividend Type
Structure Type
Growth/Value
Market Cap
Option/Short
Yes / Yes
Tags
Tags
Tags
Tags
Tags
Tags
Tags
-
Sector/Theme
Region
SMA20
3.78%
SMA50
9.74%
SMA200
18.68%
Return% 1Y
66.37%
Return% 3Y
15.33%
Return% 5Y
-7.01%
Return% 10Y
Return% SI
Flows% 1M
6.23%
Flows% 3M
11.63%
Flows% YTD
15.47%
Flows% 1Y
Flows% 3Y
Flows% 5Y
Trades
Total Holdings
64
AUM
201.14M
NAV/sh
52W High
34.97 -4.05%
52W Low
20.93 60.30%
Volatility
2.23% 2.11%
ATR (14)
0.75
RSI (14)
61.74
Beta
0.93
Rel Volume
1.10
Avg Volume
50.50K
Volume
55,512
Perf Week
-3.90%
Perf Month
14.90%
Perf Quarter
13.23%
Perf Half Y
20.08%
Perf YTD
28.10%
Perf Year
55.04%
Perf 3Y
41.08%
Perf 5Y
-33.64%
Perf 10Y
-
Prev Close
34.50
Price
33.55
Change
-2.75%
Feb-24-26 08:00AM
Jan-09-26 10:00AM
May-02-25 03:25AM
Apr-30-25 04:35AM
04:33AM
05:45AM Loading…
Apr-23-25 05:45AM
Apr-20-25 11:28AM
Apr-18-25 01:40PM
Apr-04-25 08:30AM
Apr-02-25 07:00AM
Apr-01-25 05:40AM
Mar-28-25 06:05AM
Mar-20-25 04:32PM
Sep-09-22 01:45PM
Mar-30-22 01:30PM
09:59PM Loading…
Feb-25-22 09:59PM
Dec-06-21 10:15AM
Oct-21-21 10:15AM
May-18-20 03:42PM
10:51AM
Dec-23-19 12:00PM
Dec-18-19 01:41PM
Nov-25-19 06:55PM
Nov-21-19 12:56PM
Nov-04-19 01:00PM
Oct-23-19 10:10AM
Sep-06-19 03:07PM
Sep-04-19 03:18PM
iShares Genomics Immunology and Healthcare ETF seeks to track the investment results of the NYSE FactSet Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.